Non-Small Cell Lung Cancer (NSCLC)

Alectinib improves disease-free survival in patients with ALK-positive non–small-cell lung cancer.

Central nervous system progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.

Neoadjuvant nivolumab combination followed by surgery and adjuvant nivolumab show an improvement in event-free survival for patients with previously untreated resectable stage II to IIIB non-small cell lung cancer.

Results from the phase 2 PERLA trial showed an improved objective response and overall survival in treatment with dostarlimab plus chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Data from the phase 2 KRYSTAL-7 study support a phase 3 trial assessing concurrent adagrasib plus pembrolizumab compared with pembrolizumab alone in treatment-naïve KRAS G12C-mutated non–small cell lung cancer.

Data from a phase 1a/1b trial support additional research on dual TIGIT/PD-L1 inhibition in patients with advanced solid tumors.

The FDA companion diagnostic designation for the FoundationOne CDx and FoundationOne Liquid CDx may improve access to treatment with encorafenib plus binimetinib for those with BRAF V600E-mutated non–small cell lung cancer.

Those with resectable non–small cell lung cancer can now receive neoadjuvant treatment with pembrolizumab and chemotherapy followed by adjuvant pembrolizumab after approval by the FDA.

Results from the phase 3 FLAURA2 trial allowed for the combination of osimertinib plus chemotherapy to be submitted for priority review.

Kristen Neumann, DNP, FNP-C, highlights the value of a multidisciplinary approach in the care of patients with EGFR-mutated non-small cell lung cancer, emphasizing the roles of dermatologists, pharmacists, and nurses in ensuring thorough patient assessment and education; Misako Nagasaka, MD, PhD, highlights data from WCLC 2023 on osimertinib in EGFR-mutated NSCLC.

Kristen Neumann, DNP, FNP-C, emphasizes the importance of early assessment and potential dose reductions or holds when patients on treatment for EGFR-mutated non-small cell lung cancer show adverse effects, while Misako Nagasaka, MD, PhD, stresses the need for accurate symptom history and supporting lab work to ensure patient safety.

Patients diagnosed with BRAF V600E–mutant, metastatic non–small cell lung cancer are now able to undergo treatment with combination encorafenib and binimetinib.

Investigators plan to share data from the phase 3 KEYNOTE-671 trial assessing perioperative pembrolizumab in resectable non–small cell lung cancer with international regulatory health authorities.

Kristen Neumann, DNP, FNP-C, and Misako Nagasaka, MD, PhD, discuss the importance of patient education on diarrhea as a side effect of EGFR-mutated non-small cell lung cancer treatment, emphasizing dietary considerations and the use of over-the-counter remedies.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, a family nurse practitioner with 30 years of experience in oncology, discuss EGFR-mutated non-small cell lung cancer, the available treatment options, and common side effects such as rash, emphasizing patient education and proactive management for side effects.

Members of the committee reviewed findings from the phase 3 CodeBreaK200 trial, assessing the benefit of sotorasib in KRAS G12C–mutant non–small cell lung cancer.

Investigators will present overall survival and objective response data from the phase 3 MARIPOSA-2 trial assessing amivantamab in EGFR exon 19 deletion–positive non–small cell lung cancer at a future scientific meeting.

MYTX-011 is being assessed as part of the phase 1 KisMET-01 study in patients with locally advanced, recurrent or metastatic non–small cell lung cancer.

Investigators of the phase 3 CheckMate-77T trial report positive findings for patients with nonmetastatic non–small cell lung cancer who were treated with neoadjuvant nivolumab and chemotherapy.

Pembrolizumab plus lenvatinib does not improve objective response rate compared with standard-of-care treatment among patients with metastatic non–small cell lung cancer in the phase 3 LEAP-006 and LEAP-008 trials.

Investigators of the phase 1b/2 KontRASt-01 trial will continue their evaluation of TNO155 plus JDQ433 in KRAS G12C-mutated solid tumors as part of an expansion portion of the trial.

Treatment with zongertinib produces low rates of EGFR-mediated adverse effects among patients with HER2-mutated non–small cell lung cancer in the phase 1a/b BEAMION Lung-1 trial.

Baseline characteristics do not appear to correlate with long-term benefits for patients receiving durvalumab plus tremelimumab and chemotherapy for metastatic non–small cell lung cancer in the phase 3 POSEIDON trial.

Findings from the phase 3 AEGEAN trial suggest that patients with EGFR-mutated non–small cell lung cancer experience similar outcomes whether receiving durvalumab or placebo.

Treatment with adagrasib appears to be particularly well tolerated in patients with KRAS G12C–mutated non–small cell lung cancer who receive it for more than 1 year.

Iruplinalib appears tolerable with no new safety signals among patients with locally advanced and metastatic ALK-positive non–small cell lung cancer in the phase 3 INSPIRE trial.

Data from the phase 2 EVOKE-02 trial support further assessment of sacituzumab govitecan plus pembrolizumab as a frontline treatment for metastatic non–small cell lung cancer.

Investigators report a progression-free survival benefit with osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer across all subgroups in the phase 3 FLAURA2 study.

Findings from a real-world cohort study may support renewed attention to completing molecular genotyping before first-line therapy for patients with metastatic nonsquamous non–small cell lung cancer.

Investigators report no new safety signals with alectinib as a treatment for those with early-stage, ALK-positive non–small cell lung cancer in the phase 3 ALINDA study.